Concentrations of rhIFN-α2b in rabbit plasma and lymph
Description
This is a raw data from the study of plasma and lymph pharmacokinetic profiles of recombinant human interferon alpha-2b (rhIFN-α2b), administered to rabbits by rectal and subcutaneous routes. Each animal received either Viferon® (Feron, Russia) in dosage form of rectal suppositories or Altevir® (PHARMAPARK LLC, Russia) in the dosage form of solution for injections. In both cases the administered dose of rhIFN-α2b was 1.0 mln IU/kg. Detection and quantification of rhIFN-α2b in plasma and lymph samples (n = 6 in each subgroup) were done using prevalidated sandwich ELISA. The range of analytical procedure was from 2 to 240 pg/ml (0.6-72.0 IU/ml). Data shows concentrations of rhIFN-α2b, measured in two matrices at different timepoints from 0 to 24 h after drug administration. Data codebook: time = time (hours) of blood or lymph collection after drug administration; drug = name of administered drug; matrix = matrix in which analyte concentration was measured; animal = number of rabbit in a subgroup; conc = concentration (IU/ml) of rhIFN-α2b. We found that plasma and lymph concentrations of rhIFN-α2b after s.c. administration were nearly the same at each sampling timepoint. However, after rectal administration the peak concentration of rhIFN-α2b was more than 13 times higher in lymph compared to plasma, with maximum lymph/plasma ratio 24.2 at 4 h after administration. Our results provide an evidence of selective lymphotropic transport of rhIFN-α2b after rectal administration. Rectal route of rhIFN-α2b delivery seems to be superior to s.c. route especially for the treatment of lymphatics-associated diseases, e.g. some viral infections and cancer.